Head-to-head · WeighScore
Fierce Health vs He & She MD
The verdict
He & She MD takes it — 71.5/100 to 56.6/100.
He & She MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. He & She MD is a nationwide telehealth weight-loss clinic offering doctor-prescribed GLP-1 medications: compounded semaglutide and tirzepatide (injectable or oral) plus a microdose option, with brand-name…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fierce Health | He & She MD |
|---|---|---|
| WeighScore | 56.6/100 | 71.5/100 |
| Grade | C | C |
| Scorecard rank | #410 | #91 |
| Semaglutide | $297/mo (3-month plan, compounded) | $139/mo (starting dose, promotional rate, compounded) |
| Tirzepatide | $497/mo (3-month plan, compounded) | $199/mo (starting dose, compounded) |
| Coverage | 30 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #410 · C
Strengths
- 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer on every product page
- Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
- Microdose tier at $197/mo is one of the lower entry points we've seen
Where it loses points
- No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
- Operating LLC name not disclosed anywhere on the site
- Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
- Clinical provider network not named
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #91 · C
Strengths
- Transparent intro pricing: injectable GLP-1 from $139/month, oral from $199, microdose from $99
- Compounded semaglutide and tirzepatide (injectable or oral) plus brand access to Ozempic, Wegovy, Zepbound
- Only charged if medication is prescribed; no hidden fees
- Free expedited shipping and unlimited board-certified clinician access
- GLP-1 coaching, nutrition guidance, and in-app progress tracking
Where it loses points
- Compounded GLP-1s are not FDA-approved finished products (per the site FDA disclaimer)
- Does not ship to Louisiana or to PO boxes
- Introductory pricing rises after the 6-month (or 3-month microdose) plan
- Cash-pay model — insurance billing not indicated
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.